{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-26-000008","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.935170+00:00","generated_at":"2026-05-15T11:49:47.621767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026","bullets":["Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.","Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.","Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.","R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-26-000008","json":"https://secwatch.observer/filing/0001701541-26-000008.json","markdown":"https://secwatch.observer/filing/0001701541-26-000008.md","text":"https://secwatch.observer/filing/0001701541-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/0001701541-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/bdtx-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:49:47.621767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}